Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand -IMS Study
Big Pharma needs to target emerging markets more aggressively - but not just the usual suspects. Brazil, Russia, India and China (BRIC) remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent they contributed last year
You may also be interested in...
Growth in "pharmerging" markets is so strong it is likely to nearly offset lost sales from genericization of some of pharma's biggest products in the next two years, IMS Health said April 20
IMS forecasts a 5 percent to 8 percent growth of global pharmaceutical sales annually through 2014.
Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers
A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB